+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
ID06656416

Randomized Study of ALTO-100 Versus Placebo in Adults With Bipolar Disorder and Major Depression Followed by Open-Label Treatment

Led by Alto Neuroscience · Updated on 2026-10-13

200

Participants Needed

68

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the antidepressant effects of ALTO-100 compared to a placebo in adults with Bipolar Disorder I or II who are currently experiencing a major depressive episode. This study aims to understand how patient characteristics may influence treatment outcomes when ALTO-100 is used along with a mood stabilizer andor an atypical antipsychotic. The trial also focuses on assessing safety, tolerability, and efficacy during a later open-label treatment phase. Participants in the study will be randomly assigned to receive either ALTO-100 at a dose of 40 mg twice daily or a matching placebo for 6 weeks during the double-blind treatment period. Those who qualify and continue will enter an open-label period lasting up to 7 weeks, where all will receive ALTO-100 40 mg twice daily. The study uses a quadruple-blind design to ensure unbiased results. During the trial, participants will undergo regular assessments of depression symptoms using scales such as the Montgomery-sberg Depression Rating Scale MADRS, Patient Health Questionnaire PHQ-9, and Clinician Global Impression Scale-severity CGI-S. Safety monitoring includes tracking adverse events, heart rate, blood pressure, weight, and suicidality over a total period of up to 13 weeks. The study evaluates changes from baseline to week 6 during the double-blind phase and continues safety assessments through the open-label period.

CONDITIONS

Brief Title

ALTO-100 in Bipolar Disorder With Depression (BD-D)

Research Team

A

Alto Neuroscience

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here